Paragon 28, Inc. (NYSE: FNA) is a leading medical device company exclusively focused on the foot and ankle orthopedic market. The Company designs products with the patient and surgeon in mind to improve outcomes, reduce ailment recurrence and complication rates, and make the procedures simpler,...
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company that is leveraging its unique Technosphere Technology, to develop and commercialize inhaled therapeutics, for the treatment of endocrine and orphan lung diseases. The Company’s work is based on the foresight of the visionary inventor and Alfred E....
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company, is developing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, an approach that has the potential to address the unmet needs in cardiovascular, metabolic and fatty liver diseases. The Company’s research is...
Aveo Pharmaceuticals, Inc. (NASDAQ: AVEO) was one of our stock picks this week based on its promising pipeline and an impending FDA approval for FOTIVDA® (tivozanib). The Company has scored a big win with its approval, which not only validates its unique approach but also...
Misonix, Inc. (NASDAQ: MSON) is building a highly differentiated surgical ultrasonic technology portfolio, to address and improve patient outcomes in neurosurgery, spine surgery, general surgery, orthopedic surgery, wound debridement, and craniomaxillofacial surgery. A world-class specialist in Ultrasonic technology, the Company’s products and services find their...
MediWound Ltd (NASDAQ: MDWD), a Company creating cutting-edge solutions for tissue repair and regeneration, recently announced its Q4 and Full-year 2020 Financial results. While the revenue was up by 23 percent, at $6.7 Million, compared to $5.4 million for the same period in 2019, product revenues...
Celsion Corporation (NASDAQ: CLSN) announced the receipt of a Fast-Track Designation from the U.S. Food and Drug Administration (FDA) for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy that is currently undergoing Phase II trials for the treatment of advanced ovarian cancer. The candidate is an IL-12...
Nemaura Medical, Inc. (NASDAQ: NMRD), a medical device technology Company developing innovative non-invasive wearable diagnostic devices, announced the official launch of BEAT®diabetes, and the availability of proBEAT™, a non-invasive, daily-wear adhesive glucose monitor. The device comes along a proBEAT™ monitor, a first-in-class non-invasive, daily-wear glucose...
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company leveraging its signal processing technology platform, has announced the sale of three PURE EP™ Systems to St. David’s HealthCare of Austin, Texas, owned by HCA Healthcare (NYSE: HCA) and the Winner of the Malcolm Baldrige National...
Galera Therapeutics (NASDAQ: GRTX), a clinical–stage Biopharmaceutical Company aiming to redefine radiotherapy in cancer, announced positive interim results from a phase 1/2 trial of GC4419 or avasopasem manganese. An investigational, highly selective small molecule superoxide dismutase mimetic, GC4419 has the potential to convert superoxide to...
